Angiotech to participate in Bank of America Conference
29 Mai 2007 - 9:00PM
PR Newswire (US)
VANCOUVER, May 29 /PRNewswire-FirstCall/ -- Angiotech
Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), a global
specialty pharmaceutical and medical device company, is scheduled
to participate in the Bank of America Healthcare Conference, which
is being held May 30 - June 1 in Las Vegas. On Wednesday, May 30,
at 10:40 am PT, Dr. William Hunter, President and Chief Executive
Officer of Angiotech, will present a five-minute overview of the
Company, followed by a 25-minute question and answer session. A
link to the live webcast of Dr. Hunter's remarks will be available
to all interested parties on Angiotech's website at
http://www.angiotech.com/ in the Investors section. Note on Forward
Looking Statements: Statements contained in this press release that
are not based on historical fact, including without limitation
statements containing the words "believes," "may," "plans," "will,"
"estimate," "continue," "anticipates," "intends," "expects" and
similar expressions, constitute "forward-looking statements" within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995 and constitute "forward-looking information" within the
meaning of applicable Canadian securities laws. All such statements
are made pursuant to the "safe harbor" provisions of applicable
securities legislation. Forward-looking statements in this release
include but are not limited to statements regarding; financial
benefits to Angiotech that could potentially be realized from
Angiotech's wound closure business, the ability of Angiotech to
commercialize the Quill(R) SRS product and to develop and
commercialize any successive product lines, that a substantial
market exists for the product, that the product will perform as
expected, that the product represents an improvement over current
wound closure methods and that these improvements could be
beneficial to physicians and to patients. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results, events or developments
to be materially different from any future results, events or
developments expressed or implied by such forward-looking
statements. Many such risks, uncertainties and other factors are
taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the
following; general economic and business conditions, both
nationally and in the regions in which we operate; market demand;
technological changes that could impact our existing products or
our ability to develop and commercialize future products;
competition; existing governmental regulations and changes in, or
the failure to comply with, governmental regulations; decisions,
and the timing of decisions, made by health regulatory agencies
regarding approval of our technology and products; the requirement
for substantial funding to conduct research and development and to
expand commercialization activities; and any other factors that may
affect performance. In addition, our business is subject to certain
operating risks that may cause the actual results expressed or
implied by the forward-looking statements in this report to differ
materially from our actual results. These operating risks include;
poor performance of the product in the clinical setting; adverse
events related to the use of the product; improper estimation of
the size of the wound closure market; adverse results or unexpected
delays in clinical development processes; our ability to attract
and retain qualified personnel; our ability to successfully
complete preclinical and clinical development of our products;
changes in business strategy or development plans; our failure to
obtain patent protection for discoveries; loss of patent protection
resulting from third party challenges to our patents;
commercialization limitations imposed by patents owned or
controlled by third parties; our ability to obtain rights to
technology from licensors; liability for patent claims and other
claims asserted against us; our ability to obtain and enforce
timely patent and other intellectual property protection for our
technology and products; the ability to enter into, and to
maintain, corporate alliances relating to the development and
commercialization of our technology and products; market acceptance
of our technology and products; our ability to successfully
manufacture, market and sell our products; the continued
availability of capital to finance our activities; our ability to
continue to integrate into our business the operations of American
Medical Instruments Holdings, Inc. and our ability to achieve the
operational and other synergies and the other commercial or
financial benefits expected as a result of that acquisition; and
any other factors referenced in our annual information form and
other filings with the applicable Canadian securities regulatory
authorities or the SEC. Given these uncertainties, assumptions and
risk factors, readers are cautioned not to place undue reliance on
such forward-looking statements. We disclaim any obligation to
update any such factors or to publicly announce the result of any
revisions to any of the forward-looking statements contained in
this prospectus to reflect future results, events or developments.
About Angiotech Angiotech Pharmaceuticals, Inc. is a global
specialty pharmaceutical and medical device company with over 1,500
dedicated employees. Angiotech discovers, develops and markets
innovative treatment solutions for diseases or complications
associated with medical device implants, surgical interventions and
acute injury. To find out more about Angiotech
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at
http://www.angiotech.com/. CONTACT: Deirdre Neary, Manager,
Investor Relations and Corporate Communications, Angiotech
Pharmaceuticals, Inc., (604) 222-7056, DATASOURCE: Angiotech
Pharmaceuticals, Inc. CONTACT: Deirdre Neary, Manager, Investor
Relations and Corporate Communications, Angiotech Pharmaceuticals,
Inc., (604) 222-7056,
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024